The Cystic Fibrosis Foundation celebrates the FDA's approval today of the lumacaftor/ivacaftor combination drug (Orkambi™) as an important advance for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation.
Site Search
Showing 51 - 60 of 93 results
News
|
|
4 min read
An observation by surfers in Australia has led to a simple, inexpensive hypertonic saline therapy.
News
|
|
3 min read
News
|
|
2 min read
News
|
|
2 min read
On September 16, 2008, the U.S. Food and Drug Administration (
News
|
|
2 min read